About
Representation
View all Representation →Consultations- Digitisation Taskforce – Final Report
- FCA Consults on Fund Product Information and Cost Disclosure CP24/30 – ShareSoc Responds
- FRC Consults on UK Stewardship Code – ShareSoc Responds
- FCA Consultation – Modernising Redress
- HMRC Consultation – IHT on Pensions
- ShareSoc Evidence to Lords on FCA Enforcement
- ShareSoc supports FCA proposal for criminal background checks on owners and controllers of financial institutions
- UK ISA: ShareSoc submits consultation response
- FCA Consultation on Enforcement Practice & Transparency
- ShareSoc response to House of Commons Education Select Committee
- UKSA and ShareSoc Submission to Labour Party Review of Financial Services
- FCA Consultation GC23/2 Financial Promotions on Social Media
- VIEW ALL CONSULTATIONS
Education
Events
View all Events →Upcoming Events- Oct27SIGnet North Leeds / Harrogate / Skipton Group Launch Meeting
- Oct27Asset Match webinar on PISCES: what it means for liquidity in private company shares
- Oct30ShareSoc Webinar with JPMorgan Asia Growth & Income plc (JAGI)
- Nov2The future of share ownership and corporate reporting: what investors need to know
- Forums
Company
ASTRAZENECA PLC (AZN)
Blog posts
Accessing Virtual Shareholder Meetings
Post Date: April 21, 2021
It is an unfortunate feature of Covid regulations that many companies have used the waivers contained in those regs to avoid meeting with their shareholders at AGMs.
It is therefore gratifying to see that some companies are at least making some effort to provide a virtual forum to meet investors.
Two companies that I follow which have offered such forums are the RIT Capital Partners investment trust (RCP) and AstraZeneca (AZN). Unfortunately, however, there is a snag. RCP say:
You will be able to ...
Kentz, Victoria, AstraZeneca, and SSE
Post Date: June 23, 2014
A number of companies on which ShareSoc has commented recently were in the news today (23/6/2014) or over the preceding weekend. Let's cover each in turn:
Kentz
Kentz received a cash offer for the company of 935p from SNC-Lavalin this morning. That's a premium of 33% to the recent share price. With such a premium and the stated support for the offer from the directors, it looks likely to succeed. This will avoid the directors of Kentz having to deal with the ...
AstraZeneca and Pfizer merger definitely off
Post Date: May 27, 2014
Pfizer have conceded defeat in their proposed offer for AstraZeneca (AZN). Ian Read, the Chief Executive of Pfizer, said it was a "missed opportunity" for both the UK and for AZN shareholders. He also said we could have had the worlds largest pharmaceutical company domiciled in the UK which would have been good for science and manufacturing in this country. He surely has a point there.
In addition he complained about the Takeover Panel rules as contributing to thwarting the deal, but ...
Thoughts on AstraZeneca
Post Date: May 4, 2014
Shareholders in AstraZeneca are no doubt pleasantly surprised by the uplift in the share price following the offers from Pfizer. The share price has doubled in the last year on improving prospects with an even sharper increase in the last few weeks as soon as a bid was rumoured. That puts the company on a historic p/e of about 20 at the time of writing.
AstraZeneca has of course been a dog for some years with falling revenue and earnings, a poor ...
AGM Reports
Report on AstraZeneca (AZN) AGM 2014
Post Date: April 28, 2014
Introduction
As a shareholder I am pleased to observe that the company appears to have advanced
considerably since the last AGM, in line with the strategy explained at the time by the
then newly appointed CEO, Pascal Soriot (PS). The market perceived the company as
having severe problems due to a “cliff” of patent expiries, impacting future revenues and
profits. Astra’s pipeline of new products, to replace revenues & profits from products
with expiring patents, was perceived as weak.
As disclosed in the annual report and in the ...
Corporate Remuneration Reports
AstraZeneca Remuneration April Report 2016
Post Date: April 25, 2016
Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful) Manifest has assessed the Company’s disclosures against the recommendations of the UK Corporate Governance Code, institutional investor guidelines and the disclosure requirements set out in both the Companies Acts and the UKLA Listing Rules. The following items have been identified which may be of interest to shareholders:
Remuneration policy establishes a strong alignment between executive remuneration and Company strategy. Total remuneration awarded/received could be deemed ...
AstraZeneca Remuneration Report 2016
Post Date: April 7, 2016
Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful). Manifest comment
Shareholders may wish to note that this resolution previously recorded a high level of dissent with 39.31%.
The targets used to determine the directors' annual bonus in respect of the year under review have not been fully disclosed.
The level of the upper bonus cap for certain of the executive directors may be of concern.
The aggregate of all long-term incentive awards made to Soriot represents ...
Become a free Associate ShareSoc member
Enter your email to sign up as a free Associate ShareSoc member and receive our emails. It takes a few seconds — and on the next page you'll have the option to customise your membership.